title: Application of hydroxyapatite nanoparticles in development of an enhanced formulation for delivering sustained release of triamcinolone acetonide.
abstract: We report an analysis of in vitro and in vivo drug release from an in situ formulation consisting of triamcinolone acetonide (TR) and poly(D,L-lactide-co-glycolide) (PLGA) and the additives glycofurol (GL) and hydroxyapatite nanoparticles (HA). We found that these additives enhanced drug release rate. We used the Taguchi method to predict optimum formulation variables to minimize the initial burst. This method decreased the burst rate from 8% to 1.3%. PLGA-HA acted as a strong buffer, thereby preventing tissue inflammation at the injection site caused by the acidic degradation products of PLGA. Characterization of the optimized formulation by a variety of techniques, including scanning electron microscopy, X-ray diffraction, differential scanning calorimetry, and Fourier transform near infrared spectroscopy, revealed that the crystalline structure of TR was converted to an amorphous form. Therefore, this hydrophobic agent can serve as an additive to modify drug release rates. Data generated by in vitro and in vivo experiments were in good agreement.
authors: Membrane Research Center, Chemical Engineering Department, Razi University, Kermanshah, Iran.
authors: Saeid
authors: S
authors: Koocheki
authors: Sayed Siavash
authors: SS
authors: Madaeni
authors: Parisa
authors: P
authors: Niroomandi
references: J Control Release. 2005 Dec 5;109(1-3):211-21
references: 16288815
references: Pharm Res. 2000 Dec;17(12):1546-50
references: 11303966
references: J Control Release. 2002 Apr 23;80(1-3):9-28
references: 11943384
references: J Control Release. 2003 Jul 31;90(3):345-54
references: 12880701
references: J Control Release. 2006 Jan 10;110(2):266-272
references: 16300851
references: Int J Pharm. 2000 Jan 25;194(2):181-91
references: 10692642
references: AAPS PharmSciTech. 2010 Sep;11(3):1138-46
references: 20652458
references: Biomaterials. 2002 Nov;23(21):4295-302
references: 12194532
references: Colloids Surf B Biointerfaces. 2010 Jan 1;75(1):1-18
references: 19782542
references: J Pharm Sci. 2000 Jun;89(6):732-41
references: 10824131
references: J Control Release. 2008 Apr 21;127(2):146-53
references: 18325617
references: J Control Release. 2008 Sep 24;130(3):220-5
references: 18611421
references: J Colloid Interface Sci. 2010 Apr 1;344(1):61-9
references: 20070971
references: Eur J Pharm Biopharm. 2007 Nov;67(3):676-81
references: 17493793
references: Int J Pharm. 2009 Feb 23;368(1-2):45-55
references: 18992313
references: J Control Release. 2009 Mar 19;134(3):186-93
references: 19121348
references: Eur J Pharm Biopharm. 2004 Sep;58(2):445-55
references: 15296966
references: J Control Release. 2000 Apr 3;65(3):375-87
references: 10699296
references: Biomed Mater Eng. 2002;12(2):157-67
references: 12122239
references: Drug Deliv. 1996;3(3):137-42
references: 26790908
references: Neurobiol Aging. 1989 Sep-Oct;10(5):631; discussion 648-50
references: 2812240
references: Pharm Res. 2011 Mar;28(3):563-71
references: 21049282